Teva Pharmaceutical Industries (TEVA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $41.50, +0.95% vs the prior close of $41.11.
- Volume 5.94M shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
TEVA rises 0.9% to $41.50, a 52-week high. Closed at $41.50, +0.95% vs the prior close of $41.11. Day range $40.96–$41.70, opened at $41.26.
TEVA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — TEVA rises 0.9% to $41.50, a 52-week high
- Closed at $41.50, +0.95% vs the prior close of $41.11. Day range $40.96–$41.70, opened at $41.26.
- Volume was 5.94M shares, 1.1x its 50-day average of 5.61M.
- Price is +8.5% vs its 50-day average ($38.27) and +21.5% vs its 200-day average ($34.15).
- 52-week range $18.83–$42.02; today's close sits at 98% of that range, 1.2% below the 52-week high.
Oct 15, 2026 — TEVA rises 1.0% to $41.11
- Closed at $41.11, +0.96% vs the prior close of $40.72. Day range $41.03–$41.85, opened at $41.30.
- Volume was 9.41M shares, 1.7x its 50-day average of 5.52M.
- Price is +7.8% vs its 50-day average ($38.13) and +20.6% vs its 200-day average ($34.10).
- 52-week range $18.83–$42.02; today's close sits at 96% of that range, 2.2% below the 52-week high.
Oct 14, 2026 — TEVA dips 1.3% to $40.72 on 1.9x normal volume
- Closed at $40.72, -1.28% vs the prior close of $41.25. Day range $40.71–$41.87, opened at $41.11.
- Volume was 10.27M shares, 1.9x its 50-day average of 5.41M — unusually heavy trading.
- Price is +7.1% vs its 50-day average ($38.00) and +19.6% vs its 200-day average ($34.05).
- 52-week range $18.83–$42.02; today's close sits at 94% of that range, 3.1% below the 52-week high.
Oct 13, 2026 — TEVA ends flat (+0.2%) to $41.25, a 52-week high, 5 up days in a row
- Closed at $41.25, +0.19% vs the prior close of $41.17. Day range $40.97–$41.65, opened at $41.23.
- Volume was 6.82M shares, 1.3x its 50-day average of 5.40M.
- Price is +8.9% vs its 50-day average ($37.88) and +21.3% vs its 200-day average ($34.01).
- 52-week range $18.83–$42.02; today's close sits at 97% of that range, 1.8% below the 52-week high.
- That makes 5 straight gains.
Oct 12, 2026 — TEVA ends flat (+0.2%) to $41.17, a 52-week high, 4 up days in a row
- Closed at $41.17, +0.17% vs the prior close of $41.10. Day range $40.60–$41.49, opened at $41.29.
- Volume was 7.56M shares, 1.4x its 50-day average of 5.34M.
- Price is +9.1% vs its 50-day average ($37.74) and +21.2% vs its 200-day average ($33.96).
- 52-week range $18.83–$42.02; today's close sits at 96% of that range, 2.0% below the 52-week high.
- That makes 4 straight gains.
Oct 9, 2026 — TEVA jumps 4.7% to $41.10, a 52-week high on 2.8x normal volume
- Closed at $41.10, +4.71% vs the prior close of $39.25. Day range $40.12–$42.02, opened at $40.22.
- Volume was 14.82M shares, 2.8x its 50-day average of 5.22M — unusually heavy trading.
- Price is +9.3% vs its 50-day average ($37.62) and +21.2% vs its 200-day average ($33.91).
- 52-week range $18.83–$42.02; today's close sits at 96% of that range, 2.2% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — TEVA ends flat (+0.2%) to $39.25
- Closed at $39.25, +0.18% vs the prior close of $39.18. Day range $38.25–$39.64, opened at $38.84.
- Volume was 5.82M shares, 1.1x its 50-day average of 5.46M.
- Price is +4.6% vs its 50-day average ($37.51) and +15.9% vs its 200-day average ($33.86).
- 52-week range $18.83–$40.79; today's close sits at 93% of that range, 3.8% below the 52-week high.
Oct 7, 2026 — TEVA ends flat (+0.1%) to $39.18
- Closed at $39.18, +0.13% vs the prior close of $39.13. Day range $38.65–$39.39, opened at $38.93.
- Volume was 3.46M shares, 0.6x its 50-day average of 5.49M.
- Price is +4.7% vs its 50-day average ($37.42) and +15.9% vs its 200-day average ($33.82).
- 52-week range $18.83–$40.79; today's close sits at 93% of that range, 3.9% below the 52-week high.
Oct 6, 2026 — TEVA dips 1.3% to $39.13
- Closed at $39.13, -1.34% vs the prior close of $39.66. Day range $38.85–$39.93, opened at $39.65.
- Volume was 5.72M shares, 1.0x its 50-day average of 5.49M.
- Price is +5.0% vs its 50-day average ($37.26) and +15.9% vs its 200-day average ($33.77).
- 52-week range $18.83–$40.79; today's close sits at 92% of that range, 4.1% below the 52-week high.
Oct 5, 2026 — TEVA rises 0.3% to $39.66
- Closed at $39.66, +0.33% vs the prior close of $39.53. Day range $39.27–$40.03, opened at $39.44.
- Volume was 4.15M shares, 0.8x its 50-day average of 5.47M.
- Price is +6.9% vs its 50-day average ($37.10) and +17.6% vs its 200-day average ($33.73).
- 52-week range $18.83–$40.79; today's close sits at 95% of that range, 2.8% below the 52-week high.
Oct 2, 2026 — TEVA rises 0.6% to $39.53
- Closed at $39.53, +0.56% vs the prior close of $39.31. Day range $39.05–$39.81, opened at $39.31.
- Volume was 4.78M shares, 0.9x its 50-day average of 5.46M.
- Price is +7.0% vs its 50-day average ($36.93) and +17.4% vs its 200-day average ($33.68).
- 52-week range $18.83–$40.79; today's close sits at 94% of that range, 3.1% below the 52-week high.
TEVA latest news & SEC filings
Every SEC filing by or about TEVA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Savage Brian converted options/RSUs into 4,503 shares at $34.70 (≈$156.25K) on Sep 18, 2026; now holds 15,842
- Savage Brian sold 4,503 shares at $38.69 (≈$174.22K) on Sep 18, 2026; now holds 11,339
- Savage Brian sold 2,525 shares at $39.15 (≈$98.84K) on Sep 18, 2026; now holds 8,814
- Savage Brian sold 314 shares at $38.70 (≈$12.15K) on Sep 18, 2026; now holds 8,500
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mignone Roberto sold 367,600 shares at $39.06 (≈$14.36M) on Sep 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 21, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 18, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 14, 2026 · Form 8-A12B/A — 8-A12B/A filing
8-A12B/A filing
Sep 14, 2026 · Form 25-NSE — Notice that a security is being removed from exchange listing
Notice that a security is being removed from exchange listing
Sep 11, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 10, 2026 · Form FWP — Free writing prospectus (offering marketing material)
Free writing prospectus (offering marketing material)
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 10, 2026 · Form FWP — Free writing prospectus (offering marketing material)
Free writing prospectus (offering marketing material)
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 8, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade TEVA
- Last results release: Jul 29, 2026 (8-K Item 2.02). Previous ones: Apr 29, 2026, Jan 28, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Oct 28, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.32% (largest 4.7%).
- Liquidity: about 6.49M shares (≈$269.18M) trade per day on average.
- 52-week position: $41.50 vs a range of $18.83–$42.02 (98% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Roberto Mignone sold 367,600 shares on Sep 18, 2026.
- Latest filings: 8-K Sep 16, 2026; 8-K Sep 14, 2026; 8-K Sep 11, 2026.
- Share count: 1.17B shares outstanding (Jun 30, 2026), +1.6% vs a year earlier.
- Listing: NYSE · industry: Pharmaceutical Preparations.
TEVA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 41.26 | 41.70 | 40.96 | 41.50 | 5.94M |
| Oct 15, 2026 | 41.30 | 41.85 | 41.03 | 41.11 | 9.41M |
| Oct 14, 2026 | 41.11 | 41.87 | 40.71 | 40.72 | 10.27M |
| Oct 13, 2026 | 41.23 | 41.65 | 40.97 | 41.25 | 6.82M |
| Oct 12, 2026 | 41.29 | 41.49 | 40.60 | 41.17 | 7.56M |
| Oct 9, 2026 | 40.22 | 42.02 | 40.12 | 41.10 | 14.82M |
| Oct 8, 2026 | 38.84 | 39.64 | 38.25 | 39.25 | 5.82M |
| Oct 7, 2026 | 38.93 | 39.39 | 38.65 | 39.18 | 3.46M |
| Oct 6, 2026 | 39.65 | 39.93 | 38.85 | 39.13 | 5.72M |
| Oct 5, 2026 | 39.44 | 40.03 | 39.27 | 39.66 | 4.15M |
| Oct 2, 2026 | 39.31 | 39.81 | 39.05 | 39.53 | 4.78M |
| Oct 1, 2026 | 39.50 | 39.58 | 38.52 | 39.31 | 5.99M |
| Sep 30, 2026 | 40.20 | 40.28 | 39.22 | 39.60 | 5.65M |
| Sep 29, 2026 | 38.90 | 40.24 | 38.67 | 39.81 | 6.82M |
| Sep 28, 2026 | 38.36 | 39.11 | 38.30 | 38.88 | 4.30M |
| Sep 25, 2026 | 40.10 | 40.25 | 38.93 | 39.19 | 3.87M |
| Sep 24, 2026 | 38.74 | 40.31 | 38.63 | 40.22 | 7.73M |
| Sep 23, 2026 | 39.68 | 40.09 | 38.92 | 39.01 | 6.14M |
| Sep 22, 2026 | 39.45 | 40.14 | 39.05 | 39.52 | 4.54M |
| Sep 21, 2026 | 39.09 | 40.79 | 38.36 | 40.06 | 5.94M |
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries (TEVA) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in TEL AVIV. State of incorporation: Israel. Fiscal year ends December 31. SEC CIK 818686.
TEVA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Sol J Barer | Director | Jun 8, 2026 |
| Rosemary A Crane | Director | Jun 8, 2026 |
| Amir Elstein | Director | Jun 8, 2026 |
| Gerald M Lieberman | Director | Jun 8, 2026 |
| Chen Lichtenstein | Director | Jun 8, 2026 |
| Roberto Mignone | Director | Sep 22, 2026 |
| Perry Nisen | Director | Jun 8, 2026 |
| Ronit Satchi-Fainaro | Director | Aug 25, 2026 |
| Tal Zvi Zaks | Director | Aug 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Richard Daniell | EVP, Europe Commercial | May 7, 2026 |
| Christine Fox | EVP, U.S. Commercial | May 4, 2026 |
| Richard D Francis | President and CEO | Jun 8, 2026 |
| Eric A Hughes | See "Remarks" | Aug 5, 2026 |
| Placid Jover | See "Remarks" | Aug 5, 2026 |
| Eliyahu Sharon Kalif | EVP, Chief Financial Officer | Jun 16, 2026 |
| Evan Lippman | EVP, Business Development | Aug 19, 2026 |
| Mark Sabag | See "Remarks" | May 4, 2026 |
| Brian Savage | Interim Chief Legal Officer | Sep 22, 2026 |
| Matthew Shields | EVP, Global Operations | Jun 22, 2026 |
| Amir Weiss | Chief Accounting Officer | Aug 25, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 18, 2026 | Roberto Mignone | Sale | 367,600 | $39.06 |
| Sep 18, 2026 | Roberto Mignone | Sale | 367,600 | $39.06 |
| Sep 18, 2026 | Roberto Mignone | Sale | 367,600 | $39.06 |
| Sep 18, 2026 | Roberto Mignone | Sale | 367,600 | $39.06 |
| Sep 18, 2026 | Brian Savage | Sale | 314 | $38.70 |
| Sep 18, 2026 | Brian Savage | Sale | 2,525 | $39.15 |
| Sep 18, 2026 | Brian Savage | Sale | 4,503 | $38.69 |
| Sep 18, 2026 | Brian Savage | Sale | 314 | $38.70 |
| Sep 18, 2026 | Brian Savage | Sale | 2,525 | $39.15 |
| Sep 18, 2026 | Brian Savage | Sale | 4,503 | $38.69 |
| Sep 18, 2026 | Brian Savage | Sale | 314 | $38.70 |
| Sep 18, 2026 | Brian Savage | Sale | 2,525 | $39.15 |
| Sep 18, 2026 | Brian Savage | Sale | 4,503 | $38.69 |
| Sep 18, 2026 | Brian Savage | Sale | 314 | $38.70 |
| Sep 18, 2026 | Brian Savage | Sale | 2,525 | $39.15 |
TEVA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $17.26B | $1.41B | 1.21 | $1.65B |
| Dec 31, 2024 | $16.54B | $-1.64B | -1.45 | $1.25B |
| Dec 31, 2023 | $15.85B | $-559.00M | -0.50 | $1.37B |
| Dec 31, 2022 | $14.93B | $-2.45B | -2.20 | $1.59B |
| Dec 31, 2021 | $15.88B | $417.00M | 0.38 | $798.00M |
Latest balance sheet: total assets $39.86B, total liabilities $32.10B, cash $3.65B (as of Jun 30, 2026).
TEVA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 29, 2026 | 8-K Item 2.02 (results) | $34.71 |
| Apr 29, 2026 | 8-K Item 2.02 (results) | $35.38 |
| Jan 28, 2026 | 8-K Item 2.02 (results) | $33.21 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $32.79 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $24.60 |
| Jul 30, 2025 | 8-K Item 2.02 (results) | $16.83 |
| May 7, 2025 | 8-K Item 2.02 (results) | $17.60 |
| Jan 29, 2025 | 8-K Item 2.02 (results) | $18.54 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $17.43 |
| Jul 31, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Jan 31, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on TEVA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.